Lexeo Therapeutics (LXEO) Short Interest Ratio & Short Volume $3.89 -0.07 (-1.77%) Closing price 04:00 PM EasternExtended Trading$3.90 +0.01 (+0.28%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Lexeo Therapeutics Short Interest DataLexeo Therapeutics (LXEO) has a short interest of 5.15 million shares, representing 22.49% of the float (the number of shares available for trading by the public). This marks a 7.74% increase in short interest from the previous month. The short interest ratio (days to cover) is 5.7, indicating that it would take 5.7 days of the average trading volume of 530,207 shares to cover all short positions.Current Short Interest5,150,000 sharesPrevious Short Interest4,780,000 sharesChange Vs. Previous Month+7.74%Dollar Volume Sold Short$20.70 millionShort Interest Ratio5.7 Days to CoverLast Record DateJune 30, 2025Outstanding Shares33,200,000 sharesFloat Size22,900,000 sharesShort Percent of Float22.49%Today's Trading Volume345,119 sharesAverage Trading Volume530,207 sharesToday's Volume Vs. Average65% Short Selling Lexeo Therapeutics? Sign up to receive the latest short interest report for Lexeo Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartLXEO Short Interest Over TimeLXEO Days to Cover Over TimeLXEO Percentage of Float Shorted Over Time Lexeo Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/30/20255,150,000 shares $20.70 million +7.7%22.5%5.7 $4.02 6/15/20254,780,000 shares $18.83 million +26.5%19.1%4.7 $3.94 5/31/20253,780,000 shares $10.43 million +21.5%15.1%3.8 $2.76 5/15/20253,110,000 shares $8.40 million -4.6%12.4%3.2 $2.70 4/30/20253,260,000 shares $12.81 million +10.9%13.0%3.7 $3.93 4/15/20252,940,000 shares $7.50 million +14.0%11.8%4 $2.55 3/31/20252,580,000 shares $8.95 million +16.2%10.3%3.9 $3.47 3/15/20252,220,000 shares $6.82 million -8.6%8.9%4.8 $3.07 2/28/20252,430,000 shares $6.95 million +5.2%9.8%7.5 $2.86 2/15/20252,310,000 shares $10.40 million +22.9%9.2%9 $4.50 Get the Latest News and Ratings for LXEO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Lexeo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20251,880,000 shares $10.21 million -18.6%8.0%5.3 $5.43 1/15/20252,310,000 shares $12.68 million +3.1%9.8%6.3 $5.49 12/31/20242,240,000 shares $14.74 million +9.3%9.4%5.9 $6.58 12/15/20242,050,000 shares $14.10 million -6.8%8.6%5.2 $6.88 11/30/20242,200,000 shares $18.11 million -11.7%9.2%5.1 $8.23 11/15/20242,490,000 shares $16.56 million +13.7%10.5%6.1 $6.65 10/31/20242,190,000 shares $17.30 million +6.3%9.8%7.6 $7.90 10/15/20242,060,000 shares $18.40 million -0.5%9.4%6.9 $8.93 9/30/20242,070,000 shares $18.71 million +74.0%9.4%6 $9.04 9/15/20241,190,000 shares $11.51 million -4.0%5.4%3.5 $9.67 8/31/20241,240,000 shares $14.27 million -36.1%5.7%4.1 $11.51 8/15/20241,940,000 shares $23.47 million +16.9%8.8%6.4 $12.10 7/31/20241,660,000 shares $20.83 million +97.5%7.7%5.6 $12.55 7/15/2024840,700 shares $10.94 million +8.4%3.9%3.2 $13.01 6/30/2024775,600 shares $12.44 million +23.4%3.6%4.6 $16.04 6/15/2024628,800 shares $10.93 million +15.8%2.9%4.4 $17.38 5/31/2024542,900 shares $9.03 million -20.7%3.1%3.6 $16.63 5/15/2024684,400 shares $9.55 million -1.7%4.5%5.3 $13.96 4/30/2024696,200 shares $8.67 million -16.8%4.3%5.9 $12.45 4/15/2024836,400 shares $10.11 million +6.8%5.2%8.1 $12.09 3/31/2024783,500 shares $12.29 million +63.4%4.9%7.3 $15.68 3/15/2024479,500 shares $7.47 million +41.3%3.0%4.4 $15.57 2/29/2024339,400 shares $4.96 million -3.6%2.1%3.6 $14.62 2/15/2024352,000 shares $5.36 million +16.8%2.8%3.6 $15.22 1/31/2024301,500 shares $5.17 million No Change2.4%2.8 $17.14 LXEO Short Interest - Frequently Asked Questions What is Lexeo Therapeutics' current short interest? Short interest is the volume of Lexeo Therapeutics shares that have been sold short but have not yet been closed out or covered. As of June 30th, traders have sold 5,150,000 shares of LXEO short. 22.49% of Lexeo Therapeutics' shares are currently sold short. Learn More on Lexeo Therapeutics' current short interest. What is a good short interest ratio for Lexeo Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. LXEO shares currently have a short interest ratio of 6.0. Learn More on Lexeo Therapeutics's short interest ratio. What is a good short interest percentage for Lexeo Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 22.49% of Lexeo Therapeutics' floating shares are currently sold short. Is Lexeo Therapeutics' short interest increasing or decreasing? Lexeo Therapeutics saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 5,150,000 shares, an increase of 7.7% from the previous total of 4,780,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Lexeo Therapeutics' float size? Lexeo Therapeutics currently has issued a total of 33,197,000 shares. Some of Lexeo Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Lexeo Therapeutics currently has a public float of 22,900,000 shares. How does Lexeo Therapeutics' short interest compare to its competitors? 22.49% of Lexeo Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Lexeo Therapeutics: Ginkgo Bioworks Holdings, Inc. (31.50%), Tyra Biosciences, Inc. (0.06%), Precigen, Inc. (19.85%), Arvinas, Inc. (10.28%), Theravance Biopharma, Inc. (9.06%), Sage Therapeutics, Inc. (5.10%), Organogenesis (15.93%), Taysha Gene Therapies, Inc. (0.70%), Abivax SA Sponsored ADR (2.68%), Bicycle Therapeutics PLC Sponsored ADR (4.87%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), Strategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks. What does it mean to sell short Lexeo Therapeutics stock? Short selling LXEO is an investing strategy that aims to generate trading profit from Lexeo Therapeutics as its price is falling. LXEO shares are trading down $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Lexeo Therapeutics? A short squeeze for Lexeo Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of LXEO, which in turn drives the price of the stock up even further. How often is Lexeo Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LXEO, twice per month. The most recent reporting period available is June, 30 2025. More Short Interest Resources from MarketBeat Related Companies DNA Short Interest TYRA Short Interest PGEN Short Interest ARVN Short Interest TBPH Short Interest SAGE Short Interest ORGO Short Interest TSHA Short Interest ABVX Short Interest BCYC Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:LXEO) was last updated on 7/22/2025 by MarketBeat.com Staff From Our PartnersTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredBitcoin just humbled Jeff BezosBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredSteve Jobs' Deathbed Secret Finally LeakedLeaked: Jobs’ Final Apple Project Exposed Bloomberg just leaked details of a secret project Steve Jobs set ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.